Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      Jubilant Life Sciences to buy Triad Isotopes radio-pharmacy business

      Jubilant Life Sciences to buy Triad Isotopes radio-pharmacy business

      Ruby Khatun Khatun7 May 2017 9:50 AM IST
      New Delhi: Jubilant Life Sciences' subsidiary Jubilant Pharma will acquire the radio-pharmacy business of US-based Triad Isotopes for an undisclosed...
      Hetero gets DCGI nod for generic chronic hepatitis C drug

      Hetero gets DCGI nod for generic chronic hepatitis C drug

      Ruby Khatun Khatun7 May 2017 9:49 AM IST
      New Delhi: Drug firm Hetero said it has received nod from the regulator DCGI for its generic Sofosbuvir and Velpatasvir combination tablets used for...
      World Health Organization to help bring cheap biosimilar cancer drugs to poor

      World Health Organization to help bring cheap biosimilar cancer drugs to poor

      Ruby Khatun Khatun7 May 2017 9:45 AM IST
      The World Health Organization (WHO) is to launch a pilot project this year to assess cheap copies of expensive biotech cancer drugs in a bid to make...
      Strides Shasuns plant completes successful USFDA inspection

      Strides Shasun's plant completes successful USFDA inspection

      Ruby Khatun Khatun7 May 2017 9:35 AM IST
      New Delhi: Drug firm Strides Shasun said the US health regulator has not made any observations after inspection of its manufacturing facility in...
      GST Jitters- Chemists not stocking Drugs, Abbott promises compensations

      GST Jitters- Chemists not stocking Drugs, Abbott promises compensations

      Ruby Khatun Khatun6 May 2017 3:24 PM IST
      Mumbai: In the wake of the goods and services tax (GST) regime introduction with effect from July 1, 2017 chemists are reported to have stopped...
      Johnson & Johnson ordered to pay 110 million dollar in U.S. talc-powder trial

      Johnson & Johnson ordered to pay 110 million dollar in U.S. talc-powder trial

      Ruby Khatun Khatun6 May 2017 2:04 PM IST
      Johnson & Johnson on Thursday was ordered by a Missouri jury to pay over $110 million to a Virginia woman who says she developed ovarian cancer...
      Novartis exercises option with Conatus for NASH product

      Novartis exercises option with Conatus for NASH product

      Ruby Khatun Khatun6 May 2017 2:04 PM IST
      Novartis is exercising its option with Conatus Pharmaceuticals for an exclusive license for the global development and commercialization of emricasan...
      GE Healthcare Receives FDA Indication Approval for Visipaque™ (iodixanol) Injection for use with coronary CT angiography

      GE Healthcare Receives FDA Indication Approval for Visipaque™ (iodixanol) Injection for use with coronary CT angiography

      Ruby Khatun Khatun6 May 2017 1:49 PM IST
      Visipaque is the first and only FDA-approved contrast agent indicated for non-invasive CCTA procedureChalfont St. Giles, UK: – Broadening its range of...
      Tata Capital Healthcare Fund advances 4 million dollar to Brinton Pharma

      Tata Capital Healthcare Fund advances 4 million dollar to Brinton Pharma

      Ruby Khatun Khatun5 May 2017 12:34 PM IST
      Tata Capital Healthcare Fund has advanced $4 million (approx Rs 25.6 crore) to Brinton Pharmaceuticals, one of the fastest growing pharmaceutical...
      Medtronic Announces Worldwide Voluntary Field Corrective action for Newport Ventillators

      Medtronic Announces Worldwide Voluntary Field Corrective action for Newport Ventillators

      Ruby Khatun Khatun5 May 2017 12:30 PM IST
      Medtronic is notifying customers worldwide of a voluntary field corrective action for all its Newport HT70 and Newport HT70 Plus ventilators...
      Novartis, Roche back French gene therapy start-up Vivet

      Novartis, Roche back French gene therapy start-up Vivet

      Ruby Khatun Khatun5 May 2017 12:25 PM IST
      French gene therapy start-up Vivet Therapeutics said on Thursday it had raised 37.5 million euros ($41 million) in an initial financing round, with...
      Merck eyes key cancer drug growth as others lose patent protection

      Merck eyes key cancer drug growth as others lose patent protection

      Ruby Khatun Khatun5 May 2017 10:38 AM IST
      Merck & Co Inc (MRK.N) on Tuesday reported better-than-expected profit in the first quarter as surprisingly strong demand for animal health...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok